Table 6.

Studys on overcoming tumor drug resistance by inducing ferroptosis.

Cancer type	Test cells	Tolerant drug	Use ferroptosis to overcome drug resistance	Reference
Colorectal cancer	HCT116 cell; HT29 cell; LOVO cell; DLD1 cell	Cisplatin	Sulfasalazine treatment can improve the anticancer activity of cisplatin	(Ma et al., 2015)
Head and neck cancer	AMC-HN3R cell; AMC-HN4R cell; AMC-HN9R cell	cisplatin	Erastin and sulfasalazine treatment can overcome resistance to cisplatin	(Roh et al., 2016; Roh et al., 2017)
Ovarian cancer	A2780 cell; A2780DDP cell	Cisplatin	Erastin and artesunate treatment can improve the anticancer activity of cisplatin	(Sato et al., 2018; Wang et al., 2015)
Ovarian cancer	A2780 cell; A2780/Taxol cell	Docetaxel	Erastin treatment can overcome resistance to docetaxel	(Zhou et al., 2019)
Non–small cell lung cancer	H3255 cell; PC9 cell; H1299 cell; A549 cell	Cisplatin	Erastin treatment can improve the anticancer activity of cisplatin	(Yamaguchi et al., 2013)
Gastric carcinoma	SC-M1 cell; AGS cell; AZ521 cell	Cisplatin	Erastin and sulfasalazine treatment can improve the anticancer activity of cisplatin	(Wang et al., 2016)
Acute myeloid leukemia	HL60 cell	Cytarabine, doxorubicin	Low-dose Erastin treatment can significantly increase the anticancer activity of cytarabine, doxorubicin	(Yu et al., 2015)
Glioblastoma multiforme	GBM-N15 cell	Temozolomide	Erastin and sulfasalazine treatment can improve the anticancer activity of temozolomide	(Chen et al. 2015)
Hepatocellular carcinoma	Huh7 cell, HepaG2 cell,Hep3b cell	Sorafenib	Inhibition of metallothionein (MT)-1G can increase sensitivity to sorafenib	(Sun et al., 2016b)